Most patients with CML harbor either the e13a2 or the e14a2 BCR-ABL fusion product, while a small subset of the cases expresses e1a2 or e19a2 transcripts. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.